Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases

Delbaere, Quentin; Chapet, Nicolas; Huet, Fabien; Delmas, Clément; Mewton, Nathan; Prunier, Fabrice; Angoulvant, Denis; Roubille, François

doi:10.3390/ph16010078

Cited by 7 publications

(3 citation statements)

References 64 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 Thus, a need exists for anti-inflammatory therapeutics to prevent and treat inflammatory diseases. [8][9][10][11] Wang et al 2018 showed that nanocomposites of collagen and silica-containing IL-10 inhibited proinflammatory cytokines and promoted wound-healing cytokines. 12 IL-10 is secreted by various cells, comprising, but not limited, to lymphocytes, monocytes, and macrophages, in response to diverse stimuli.…”

Section: Introductionmentioning

confidence: 99%

PLGA-Chitosan Encapsulated IL-10 Nanoparticles Modulate Chlamydia Inflammation in Mice

Yilma,

Sahu,

Subbarayan

et al. 2024

IJN

View full text Add to dashboard Cite

Introduction Interleukin-10 (IL-10) is a key anti-inflammatory mediator in protecting host from over-exuberant responses to pathogens and play important roles in wound healing, autoimmunity, cancer, and homeostasis. However, its application as a therapeutic agent for biomedical applications has been limited due to its short biological half-life. Therefore, it is important to prolong the half-life of IL-10 to replace the current therapeutic application, which relies on administering large and repeated dosages. Therefore, not a cost-effective approach. Thus, studies that aim to address this type of challenges are always in need. Methods Recombinant IL-10 was encapsulated in biodegradable nanoparticles (Poly-(Lactic-co-Glycolic Acid) and Chitosan)) by the double emulsion method and then characterized for size, surface charge, thermal stability, cytotoxicity, in vitro release, UV–visible spectroscopy, and Fourier Transform-Infrared Spectroscopy as well as evaluated for its anti-inflammatory effects. Bioactivity of encapsulated IL-10 was evaluated in vitro using J774A.1 macrophage cell-line and in vivo using BALB/c mice. Inflammatory cytokines (IL-6 and TNF-α) were quantified from culture supernatants using specific enzyme-linked immunosorbent assay (ELISA), and significance was analyzed using ANOVA. Results We obtained a high 96% encapsulation efficiency with smooth encapsulated IL-10 nanoparticles of ~100–150 nm size and release from nanoparticles as measurable to 22 days. Our result demonstrated that encapsulated IL-10 was biocompatible and functional by reducing the inflammatory responses induced by LPS in macrophages. Of significance, we also proved the functionality of encapsulated IL-10 by its capacity to reduce inflammation in BALB/c mice as provoked by Chlamydia trachomatis , an inflammatory sexually transmitted infectious bacterium. Discussion Collectively, our results show the successful IL-10 encapsulation, slow release to prolong its biological half-life and reduce inflammatory cytokines IL-6 and TNF production in vitro and in mice. Our results serve as proof of concept to further explore the therapeutic prospective of encapsulated IL-10 for biomedical applications, including inflammatory diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

PLGA-Chitosan Encapsulated IL-10 Nanoparticles Modulate Chlamydia Inflammation in Mice

Yilma,

Sahu,

Subbarayan

et al. 2024

IJN

View full text Add to dashboard Cite

show abstract

“…These include the central nervous system (CNS), cardiovascular system, immune system, and muscles, among others. In reality, as we get older, in addition to an insidious neurodegenerative and cognitive decrement, the functionality of the cardiovascular system is diminished by cholesterol and calcium precipitation and inflammation of the endothelial cells [2]. Similarly, the functionality of the immune system is affected, making the elderly vulnerable to cancer, infectious diseases, and activation of retrotransposons residing in the genome, inducing inflammation [3].…”

Section: Introductionmentioning

confidence: 99%

Underlying Mechanisms of Brain Aging and Neurodegenerative Diseases as Potential Targets for Preventive or Therapeutic Strategies Using Phytochemicals

Abdolmaleky

Zhou

2023

Nutrients

View full text Add to dashboard Cite

During aging, several tissues and biological systems undergo a progressive decline in function, leading to age-associated diseases such as neurodegenerative, inflammatory, metabolic, and cardiovascular diseases and cancer. In this review, we focus on the molecular underpinning of senescence and neurodegeneration related to age-associated brain diseases, in particular, Alzheimer’s and Parkinson’s diseases, along with introducing nutrients or phytochemicals that modulate age-associated molecular dysfunctions, potentially offering preventive or therapeutic benefits. Based on current knowledge, the dysregulation of microglia genes and neuroinflammation, telomere attrition, neuronal stem cell degradation, vascular system dysfunction, reactive oxygen species, loss of chromosome X inactivation in females, and gut microbiome dysbiosis have been seen to play pivotal roles in neurodegeneration in an interactive manner. There are several phytochemicals (e.g., curcumin, EGCG, fucoidan, galangin, astin C, apigenin, resveratrol, phytic acid, acacetin, daucosterol, silibinin, sulforaphane, withaferin A, and betulinic acid) that modulate the dysfunction of one or several key genes (e.g., TREM2, C3, C3aR1, TNFA, NF-kb, TGFB1&2, SIRT1&6, HMGB1, and STING) affected in the aged brain. Although phytochemicals have shown promise in slowing down the progression of age-related brain diseases, more studies to identify their efficacy, alone or in combinations, in preclinical systems can help to design novel nutritional strategies for the management of neurodegenerative diseases in humans.

show abstract

“…Presently, to counteract the detrimental effects of chronic inflammation on the cardiovascular system, researchers have initiated the exploration and implementation of various pharmacological intervention strategies ( Li et al, 2023 ). Predominantly focusing on the utilization of anti-inflammatory drugs to attenuate the severity of chronic inflammation and its associated risks, these interventions aim to offer a more secure treatment regimen for patients with cardiovascular diseases ( Delbaere et al, 2023 ).…”

Section: Introductionmentioning

confidence: 99%

Editorial: Chronic inflammation and pharmacological interventions in cardiovascular diseases, volume II

Yan,

Wang,

Cui

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases

Cited by 7 publications

References 64 publications

PLGA-Chitosan Encapsulated IL-10 Nanoparticles Modulate Chlamydia Inflammation in Mice

PLGA-Chitosan Encapsulated IL-10 Nanoparticles Modulate Chlamydia Inflammation in Mice

Underlying Mechanisms of Brain Aging and Neurodegenerative Diseases as Potential Targets for Preventive or Therapeutic Strategies Using Phytochemicals

Editorial: Chronic inflammation and pharmacological interventions in cardiovascular diseases, volume II

Contact Info

Product

Resources

About